Dietrich A. Stephan - 24 Jan 2022 Form 4 Insider Report for NeuBase Therapeutics, Inc.

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Dietrich A. Stephan
Issuer symbol
N/A
Transactions as of
24 Jan 2022
Net transactions value
$0
Form type
4
Filing time
25 Jan 2022, 12:50:15 UTC
Previous filing
05 Jan 2022
Next filing
30 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBSE Employee Stock option (right to buy) Award $0 +306,000 $0.000000 306,000 24 Jan 2022 Common Stock 306,000 $1.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total shares shall vest on the first anniversary of January 24, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months; provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date.